Search
Nitecapone
go.drugbank.com/drugs/DB20402ExperimentalNitecapone is a small molecule drug. Nitecapone has a monoisotopic molecular weight of 265.06 Da.
Categories: Compounds used in a research, industrial, or household settingTalniflumate
go.drugbank.com/drugs/DB09295InvestigationalIn addition, it is used in inflammatory conditions such as rheumatoid arthritis. … Phase I trials with talniflumate for the treatment of cystic fibrosis and COPD were completed in August 2001, and phase II trials were performed in Ireland for the treatment of cystic fibrosis but this
Actelion-1
go.drugbank.com/drugs/DB05367ExperimentalActelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.
SPP 301
go.drugbank.com/drugs/DB05290InvestigationalSPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy.
Contusugene ladenovec
go.drugbank.com/drugs/DB05322InvestigationalINGN 201(Advexin) is a replication-impaired adenoviral vector that carries the p53 gene, has been evaluated in both preclinical and clinical trials. … Advexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or chemotherapy agents.
CNS-5161
go.drugbank.com/drugs/DB05824ExperimentalCNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.
Cusatuzumab
go.drugbank.com/drugs/DB15100InvestigationalCD70 is a ligand expressed on the surface of activated lymphocytes and mature dendritic cells that, in its binding to CD27 receptors, plays an important role in cell proliferation and survival. … An overexpression of CD70 can result in the proliferation of malignant cells and has been documented in a variety of solid and hematological malignancies.
Icotinib
go.drugbank.com/drugs/DB11737InvestigationalIcotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc … . was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC).